C.Difficile Vaccine's Phase 3 Trial in Clostridoides Difficile Associated Disease Reads Out
推定確度 50%ClinicalTrials.gov[1] lists 2028-12-11 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Pfizer's phase 3 trial of C.Difficile Vaccine in clostridoides difficile associated disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 32,500 participants. The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle. This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly does not work. Participants will stay in the study until enough events have occurred to answer the main question. On average, each person is expected to take part for
1.00